<DOC>
	<DOCNO>NCT00019552</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irofulven treat patient recurrent persistent ovarian , fallopian tube , peritoneal cancer .</brief_summary>
	<brief_title>Irofulven Treating Patients With Recurrent Persistent Ovarian , Fallopian Tube , Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine clinical activity irofulven patient recurrent persistent ovarian epithelial cancer . II . Characterize pharmacokinetic profile drug patient . III . Determine pharmacodynamic relationship plasma concentration clinical activity toxicity drug patient . OUTLINE : Patients stratify accord number prior treatment regimen ( 1-2 v 3 ) . Patients receive irofulven IV 5 minute day 1-5 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients follow every 4 week death . PROJECTED ACCRUAL : A maximum 74 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent persistent ovarian epithelial cancer , primary fallopian tube cancer , primary peritoneal cancer fail prior standard chemotherapy Measurable disease No history brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Greater 2 month Hematopoietic : Granulocyte count least 1,500/mm3 Hemoglobin least 9.0 g/dL ( transfusion allow ) Platelet count least 100,000/mm3 Hepatic : Bilirubin normal ALT AST great 2.5 time normal PT PTT great 1.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Urinalysis normal BUN normal Electrolytes normal Cardiovascular : No unstable newly diagnose angina pectoris within past 6 month No myocardial infarction within past 6 month No New York Heart Association class IIIV congestive heart failure Pulmonary : No chronic obstructive lung disease require oxygen supplementation therapy medication Other : No medical surgical complication require intervention , : Impending bowel obstruction Active infection No lifethreatening illness No nonskin malignancy melanoma within past 4.5 year except curatively treat malignancy low risk recurrence surgically cure stage I endometrial cancer No uncontrolled seizure Not pregnant nursing HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Recovered prior biologic therapy No prior bone marrow transplantation Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy : Recovered prior endocrine therapy Radiotherapy : Recovered prior radiotherapy No prior external beam radiotherapy Surgery : Recovered prior surgery Other : At least 1 week since prior antibiotic</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>